Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Phase 1 Dose-Escalation and Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of PRTH-101 Alone or in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

NCT05753722 is registered in ClinicalTrials.gov with Incendia Therapeutics as lead sponsor.

NCT NCT05753722
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05753722 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Phase 1 Dose-Escalation and Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of PRTH-101 Alone or in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
Lead sponsor
Incendia Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
March 3, 2023
Completion date
September 2, 2026
Enrollment
79 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic solid tumors, non small cell lung cancer, nsclc